Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Paz J. Vellanki"'
Autor:
Elitza Palazov, Yangbing Li, Harpreet Singh, Jeanne Fourie Zirkelbach, Julia A. Beaver, Dianne Spillman, Arūnas Girčys, Jiang Liu, Aleksandr Gamarian, Huiming Xia, Qiuyi Choo, Paz J. Vellanki, Pallavi S. Mishra-Kalyani, Nataliya Fesenko, Nicole Drezner, Ulrich-Peter Rohr, Richard Pazdur, Yuan Li Shen, Xiaoxue Li, Abigail L. Koch
Publikováno v:
Clinical Cancer Research. 27:6638-6643
On December 18, 2020, the FDA approved osimertinib as adjuvant therapy in patients with non–small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 (L858R) mutations, as detected by an FDA-approved test. The approval was
Autor:
Paz J. Vellanki, Hyunseok Kang, Lynn M. Schuchter, Mary Armanios, Ranee Mehra, Lisa M. Rooper, M. Malek Bawadkji, Emily A. DeBoy
Publikováno v:
JCO Precis Oncol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c80ca8dab1f2c6e573148398413b38d
https://europepmc.org/articles/PMC8457871/
https://europepmc.org/articles/PMC8457871/
Autor:
Somak Chatterjee, Martha Donoghue, Pallavi S. Mishra-Kalyani, Harpreet Singh, Erin Larkins, Hong Zhao, Missiratch Biable, Youwei Bi, Julia A. Beaver, Jiang Liu, Hisham Qosa, Richard Pazdur, Erica C Nakajima, Paz J. Vellanki, Lauren Tesh Hotaki, Yuan Li Shen
Publikováno v:
Clin Cancer Res
On October 2, 2020, FDA approved nivolumab with ipilimumab as first-line treatment for adult patients with unresectable malignant pleural mesothelioma (MPM). The approval was based on results from Study CA209743 (CHECKMATE-743), an open-label trial o
Autor:
Yibo Wang, Yuan Xu, Adnan A. Jaigirdar, Sarah J. Golding, Dianne Spillman, Victoria Mansell, Flora Mulkey, R. Angelo de Claro, Kwadwo Korsah, Grant Howe, Julia A. Beaver, Richard Pazdur, Harpreet Singh, Jiang Liu, Qiuyi Choo, Paz J. Vellanki, Jian Wang, Hong Zhao, Lisa Rodriguez
Publikováno v:
Clin Cancer Res
On May 26, 2020, the U.S. Food and Drug Administration (FDA) approved nivolumab with ipilimumab and two cycles of platinum-doublet chemotherapy as first-line treatment for patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with
Autor:
Harpreet Singh, Patricia Keegan, Paz J. Vellanki, Kunthel By, Erin A. Larkins, Shanthi Marur, Andrew T Girvin, Frank C. Cross, Marc R. Theoret, Pallavi S. Mishra-Kalyani, Richard Pazdur, Pradeep Bandaru, Somak Chatterjee
Publikováno v:
Journal of Clinical Oncology. 38:6509-6509
6509 Background: Recent evidence suggests that treatment with systemic antibiotics (Abx) disrupts the intestinal microbiome and may be associated with decreased survival for patients receiving treatment with ICIs for advanced cancers, including R/M H
Autor:
Leslie R. Ellis, Bernard Tawfik, Dmitriy Berenzon, Kavya Kannan, Susan Lyerly, Timothy S. Pardee, Paz J Vellanki, Allison Winter, Margaret Murray, Heidi D. Klepin, Bayard L. Powell, Dianna S. Howard
Publikováno v:
Journal of Clinical Oncology. 34:e18509-e18509
e18509Background: The standard of care for acute myeloid leukemia (AML) is to pursue re-induction chemotherapy if ≥ 5% blasts are present on the nadir bone marrow (BM) biopsy after induction chemot...